Fortive is recovering, but tariffs still bite
- Fortive is now a more focused company after spinning off Precision Technologies into Ralliant in June 2025.
- Q1 2026 core revenue grew 5.3%, helped by about 150 basis points from extra selling days.
- Adjusted EBITDA margin reached 29.3%, up 140 basis points, showing better operating leverage.
- Tariffs cut adjusted gross margin by about 100 basis points, and management does not expect relief until Q4.
- Finn's overall score is middling, so the page treats the recovery as real but not yet proven.
A cleaner Fortive is showing life
Fortive looks past the worst of its post-spin reset. In Q1 2026, core revenue grew 5.3%. That included about 150 basis points from extra selling days, so the cleaner demand signal was closer to 3.8%. That is still a clear improvement after 2025, when growth leaned on price while volume declined.
The bull case is about focus and leverage. Fortive now centers on Intelligent Operating Solutions and Advanced Healthcare Solutions after the Precision Technologies spin-off into Ralliant. Q1 adjusted EPS was $0.70, up 25.4% year over year, and adjusted EBITDA margin expanded 140 basis points to 29.3%. Management also reaffirmed full-year adjusted EPS guidance of $2.90 to $3.00 and said results were trending toward the upper half.
The bear case has not disappeared. Tariffs lowered adjusted gross margin by about 100 basis points, and management expects that headwind to last until Q4. There is also a growth math question. If full-year core growth is expected at only 2% to 3%, then the strong Q1 start may imply slower growth later in the year.
The next proof points are simple: Q2 core growth without calendar help, order trends in IOS and AHS, and real progress on tariff mitigation. Fortive is improving, but the score stays moderate because the recovery still needs more than one strong quarter.
Workflow tools with repeat demand
Fortive makes tools, software, and services used in jobs where errors are costly. Its products help factories test equipment, utilities manage assets, hospitals track instruments, and safety teams monitor workers. Customers often keep using these systems because they sit inside daily workflows.
The current Fortive is built around two segments. Intelligent Operating Solutions sells test tools, facility and asset software, and connected safety products. Advanced Healthcare Solutions sells sterilization, tracking, biomedical testing, radiation detection, and clinical productivity tools.
Money comes from a mix of equipment sales, software, services, and recurring workflow use. That mix can support steady margins when volumes recover. In Q1 2026, Fortive also used capital for shareholders, repurchasing 8.9 million shares for about $500 million.
The model breaks if customers delay projects, hospital budgets tighten, tariffs stay high, or acquired products fail to fit. Fortive also has to manage post-separation liabilities tied to Ralliant and leadership changes from 2025 into early 2026.
What Fortive sells
Electrical test and measurement tools
These tools help technicians test electrical systems and equipment. They are used in factories, utilities, and service work where reliability matters.
Facility and asset lifecycle software
This software helps customers track buildings, equipment, maintenance, and compliance work. It supports the recurring-revenue focus of the new Fortive.
Connected worker safety solutions
These products help monitor worker safety in industrial and field settings. Demand is tied to safety rules and the need to avoid costly incidents.
Sterilization and instrument tracking
Hospitals use these systems to clean, track, and manage medical instruments. The work is routine but critical, which can make demand more stable.
Biomedical test and radiation detection tools
These tools help healthcare providers test medical equipment and detect radiation exposure. They serve regulated workflows with a low tolerance for mistakes.
Clinical productivity software
This software helps healthcare teams manage work more efficiently. It could become a larger growth driver if hospitals keep spending on productivity tools.
Two main engines now
The mix uses Q1 2026 sales: about $743 million from Intelligent Operating Solutions and $326 million from Advanced Healthcare Solutions. This is post-spin Fortive, after Precision Technologies became Ralliant.
What could break the recovery
Tariffs stay in the margin
Medium impact · Medium oddsTariffs lowered adjusted gross margin by about 100 basis points in Q1 2026. Management does not expect full mitigation until Q4, so the pressure could last for most of the year. If pricing or sourcing actions fail, the EPS beat may not repeat.
Core growth slows after the strong start
High impact · Medium oddsQ1 core revenue growth was 5.3%, but about 150 basis points came from extra selling days. That leaves underlying growth near 3.8%. Since full-year core growth guidance is only 2% to 3%, investors should expect or fear slower growth later in the year.
Post-spin costs and Ralliant liabilities surprise investors
Medium impact · Low oddsFortive completed the Precision Technologies spin-off into Ralliant on June 28, 2025. The company has warned that indemnification liabilities to Ralliant could hurt cash flow and results. This is not the main thesis, but it can still reduce the value of the cleaner Fortive story.
Leadership transition distracts execution
Medium impact · Medium oddsThe 2025 10-K added risk language around CEO, CFO, and Chief People Officer transitions in 2025 and early 2026. That matters because Fortive is also managing a new post-spin structure and tariff pressure. Execution risk is higher when several senior roles change at once.
AI and cyber risks hit trusted workflows
Medium impact · Low oddsFortive uses artificial intelligence in parts of its business and certain products. The company warned of risks tied to accuracy, intellectual property, data privacy, and cybersecurity. These risks matter more because customers use Fortive tools in regulated and safety-sensitive workflows.
In one breath
What does Fortive do?
Fortive sells tools, software, and services for industrial and healthcare workflows. Its products help customers test equipment, manage assets, protect workers, sterilize instruments, and improve clinical productivity.
What happened to Fortive's Precision Technologies segment?
Fortive completed the spin-off of Precision Technologies into Ralliant on June 28, 2025. The remaining Fortive is mainly Intelligent Operating Solutions and Advanced Healthcare Solutions.
Why did Fortive's Q1 2026 results matter?
Q1 showed a real rebound, with 5.3% core revenue growth and adjusted EPS up 25.4% year over year. The open question is whether that strength lasts after the benefit from extra selling days fades.
What is the main risk for Fortive right now?
The main watch item is whether growth and margins can hold up. Tariffs hurt gross margin in Q1 2026, and full-year guidance suggests growth may slow after the strong start.